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that only 10% of the world’s population was covered by any one 
of the measures, and identified wide variation in the implementa-
tion of mpower measures within Africa.(4)
Physicians can make contributions to all aspects of tobacco control, 
for example through advocacy, policy development, political 
engagement and role modelling. But for most doctors, the most 
direct opportunity to reduce smoking will be in the clinical setting, 
through encouraging individuals to stop smoking and developing 
services to support them in doing so. My objective here is to review 
the evidence for the effectiveness of smoking cessation inter-
ventions available to the physician advising patients how to stop 
smoking. The available interventions include behavioural inter-
ventions (brief advice, self-help materials, counselling), comple-
mentary therapies (hypnotherapy and acupuncture) and phar-
macological therapy (nicotine replacement, antidepressants and 
the nicotine partial receptor agonist Varenicline). 
Methods                                                                          
The principal data sources are reviews of interventions for smoking 
cessation from the Cochrane Database of Systematic Reviews. The 
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Tobacco use remains the most significant modifiable contributor 
to the prevalence of cardiovascular and respiratory disease in 
high income countries. The success of tobacco control policies 
is reducing this prevalence in many of these countries, but the 
burden of tobacco related chronic disease is increasing in low 
and middle income countries as the prevalence of smoking rises. 
Smoking also increases mortality from tuberculosis and other 
diseases already more prevalent in middle and lower income 
countries.(1,2) For these reasons, if current patterns of consumption 
continue, it is estimated that by 2030, 70% of tobacco-related 
deaths worldwide will take place in developing countries.(3) To 
avert this public health catastrophe, robust tobacco control 
strategies are of central importance to all sectors of the world’s 
population. In recognition of the importance of tackling this 
threat to health, over 160 countries are signatories to the World 
Health Organisation Framework Convention on Tobacco Control. 
The WHO FCTC emphasises the importance of multimodal 
approaches to tobacco control. Its mpower strategy highlights 
six key mechanisms to reduce demand for smoking: through 
monitoring, enforcement of smoke-free environments, provision 
of cessation programmes, and imposition of health warnings, 
advertising bans and taxation. In its 2009 report, WHO estimated 
this article examines the role of doctors in assisting patients 
who smoke to quit, using evidence from cochrane systematic 
reviews of randomised trials. doctors may help such patients 
by providing advice, referring patients for counselling and 
support and by offering pharmacological therapy. comple-
mentary therapies used for smoking cessation include 
hypnotherapy and acupuncture, but there is a lack of evidence 
that these interventions have a specific effect in aiding 
cessation. the number needed to treat (nnt) for simple 
advice to unselected smokers is 50 - 120. based on a median 
no-treatment clinical trial quit rate of 7.5%, the nnt for 
nicotine replacement therapy is 23 (95% cI 20 to 27), for the 
antidepressant bupropion 18 (95% cI 14 to 23), and for the 
nicotinic partial agonist Varenicline 10 (95% cI 7 to 14). 
these numbers compare favourably with other preventive 
healthcare interventions. there remains wide variations in 
the extent to which these interventions are available in 
different healthcare systems. SAHeart 2011; 8:24-27
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Cochrane Tobacco Addiction Review Group maintains a register 
of controlled trials in smoking cessation. Systematic reviews based 
on this register are published in the Cochrane Library, and are 
regularly updated. Detailed bibliographies of the included trials can 
be found within each review. 
The aim of these reviews is to identify and synthesise the most 
reliable evidence evaluating interventions for smoking cessation. 
For individual patient interventions, the most reliable evidence 
comes from randomised controlled trials. In the Cochrane reviews, 
the principal outcome is sustained smoking cessation, defined as 
being at least six months after the intervention. Where appropriate, 
meta-analyses of individual trials provide a summary estimate of 
the effect of the interventions tested. This pooled estimate is 
expressed as a relative risk with 95% confidence intervals, where a 
relative risk greater than one indicates a higher likelihood of 
abstinence. 
AdVIce froM A doctor                                              
Physician advice to quit smoking is an inexpensive intervention, 
which can be offered in most healthcare settings. A Cochrane 
review of physician advice identified 41 trials, conducted between 
1972 and 2007, including over 31 000 participants.(5) The most 
common setting for delivery of advice was primary care, but 
there were also studies in hospital wards, outpatient clinics, and 
workplace clinics. Meta-analysis of 17 trials of brief advice versus 
no advice (or usual care) detected a significant increase in the 
rate of quitting (relative risk [RR] 1.66; 95% confidence interval [CI] 
1.42 to 1.94). There is little evidence as to whether giving the 
advice in different ways is more or less effective, though there is a 
small additional benefit from spending more time with the patient: 
Amongst 11 trials of more intensive advice the estimated effect 
was higher (RR 1.84; 95% CI 1.60 to 2.13) but there was no 
statistical difference between the intensive and minimal sub- 
groups. Direct comparison of intensive versus minimal advice 
showed a small advantage of intensive advice (RR 1.37; 95% CI 
1.20 to 1.56), and this effect may be greater in patients with 
medical conditions related to smoking, such as cardiac and res-
piratory disease, than in apparently healthy smokers. There was 
insufficient evidence to draw any conclusion about the effect of 
motivational as opposed to simple advice or between different 
advice-giving styles.
self-help MAterIAls                                                    
Self-help materials in various formats are a low cost option for 
supporting smoking cessation, but their effectiveness is low. In 12 
trials involving 15 711 participants that compared self-help materials 
to no intervention, a Cochrane review (search date 2008) found 
a pooled effect that just reached statistical significance (RR 1.21; 
95% CI 1.05 to 1.39).(6) The review did not detect a benefit from 
adding self-help materials to brief advice, or to nicotine replace-
ment therapy. There were 25 trials using materials tailored for the 
characteristics of individual smokers, where meta-analysis sup-
ported a small benefit of tailored materials (RR 1.31; 95% CI 1.20 
to 1.42). The evidence is strongest for tailored materials compared 
to no intervention, but also supports tailored materials as more 
helpful than standard materials. Part of this effect could be due 
to the additional contact or assessment required to obtain indivi-
dual data. 
counsellIng                                                                
Counselling can be provided to those seeking to quit smoking 
either through face to face contact with an individual healthcare 
worker or in group settings. A Cochrane review of individual 
counselling identified 30 trials with over 7 000 participants.(7) It 
found that individual counselling was more effective than a mini- 
mal intervention, with a relative risk for smoking cessation at long-
term follow up of 1.39, 95% CI 1.24 to 1.57. Counselling pro- 
vided additional benefit in patients receiving NRT. The review was 
unable to detect whether any specific form of counselling was 
more effective than another. A Cochrane review of group coun-
selling (search date 2008) found similar effects in the group setting, 
but poor attendance at group counselling limits the usefulness of 
this approach.(8) Face to face intervention may not be crucial to 
the success of counselling. A Cochrane review of telephone 
counselling (search date 2008) found that both proactive and 
reactive quit lines improve quit rates to a similar degree.(9)
nIcotIne replAceMent therApy                           
Nicotine replacement therapy (NRT) aims to aid smoking cessa-
tion by providing nicotine to reduce withdrawal symptoms and 
craving. It is appropriate for patients who show evidence of nico-
tine dependence, usually those who smoke more heavily, start 
early in the day and have withdrawals symptoms when they stop 
smoking. Nicotine is available as transdermal patches, chewing gum, 
nasal spray, as an inhaler and as sublingual lozenges. A Cochrane 
review of NRT (search date 2007) identified 132 trials.(10) Within 
these trials over 40 000 participants contributed to the primary 
comparison between any type of NRT and a placebo or non-NRT 
control group. The RR of abstinence for any form of NRT relative 
to control was 1.58 (95% CI 1.50 to 1.66). There were no significant 
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differences between the effects obtained using different nicotine 
products. The effects were largely independent of the duration of 
therapy, the intensity of additional support provided, or the setting 
in which the NRT was offered. There was some evidence of a small 
benefit from combining the nicotine patch with a form allowing ad 
lib dosing compared to use of a single form. Use of combination 
therapy may be considered for patients who have been unable to 
quit using a single type of NRT. There was borderline evidence 
that there is a small benefit from use of the nicotine patch at doses 
higher than 22mg (24 hours), or 15mg (16 hours) compared to 
the standard dose patch. Use of these may be considered for 
heavy smokers (i.e. smoking 30 or more cigarettes a day), or for 
patients relapsing because of persistent craving and withdrawal 
symptoms on standard dose therapy. There is limited evidence that 
a repeated course of NRT in patients who have relapsed after 
recent use of nicotine patches, will result in a small additional 
probability of quitting. One study directly compared NRT with 
Bupropin. Quit rates with Bupropion were higher than with nico-
tine patch or placebo.(11) Although there is an additional benefit 
when NRT is combined with behavioural support, NRT increases 
cessation rates whether behavioural support is provided or not, 
so it is still worth suggesting NRT if the resources are not available 
to provide such support. 
AntIdepressAnts                                                           
There is increasing evidence that some antidepressants help 
smoking cessation. They may act by alleviating depressive symp-
toms associated with nicotine withdrawal, by substituting for 
antidepressant effects of nicotine that sustain smoking, or by acting 
on neural pathways that underlie nicotine addiction. A Cochrane 
review (search date 2009) identified 66 trials of antidepressants 
for smoking cessation, including 49 trials of Bupropion and nine 
trials of Nortriptyline.(12) Bupropion (RR 1.69; 95% CI 1.53 to 1.85) 
and Nortriptyline (RR 2.03; 95% CI 1.48 to 2.78) both significantly 
increased long term cessation, but selective serotonin reuptake 
inhibitors were not shown to help smoking cessation. Bupropion 
and Nortriptyline appear to be of similar efficacy to nicotine 
replacement therapy. Pooling three trials comparing Bupropion to 
the nicotine receptor agonist Varenicline, showed lower quitting 
with Bupropion (RR 0.66; 95% CI 0.53 to 0.82). There is a risk 
of about 1 in 1 000 of seizures associated with Bupropion use. 
Bupropion has been associated with suicide risk, but whether this 
is causal is unclear. Nortriptyline has the potential for serious 
side-effects, but none have been seen in the few small trials for 
smoking cessation. 
nIcotIne receptor pArtIAl AgonIsts               
Nicotine receptor partial agonists may help people to stop 
smoking by a combination of maintaining moderate levels of 
dopamine to counteract withdrawal symptoms (acting as an 
agonist) and reducing smoking satisfaction (acting as an antagonist). 
Varenicline was developed as a nicotine receptor partial agonist 
from Cytisine, a drug widely used in central and eastern Europe for 
smoking cessation. The first trial reports of Varenicline were 
released in 2006. A Cochrane review (search date March 2008) 
included 7 267 participants from nine randomised controlled trials 
of Varenicline.(13) Seven trials compared Varenicline with placebo 
for smoking cessation and three compared it with Bupropion. 
There was one trial of relapse prevention and one open-label trial 
that compared Varenicline with nicotine replacement therapy. 
The pooled risk ratio for continuous abstinence for Varenicline 
versus placebo was 2.33 (95% CI 1.95 to 2.80). The pooled RR for 
Varenicline versus Bupropion at one year was 1.52 (95% CI 1.22 
to 1.88). The RR for Varenicline versus NRT at one year was 1.31 
(95% CI 1.01 to 1.71). The main adverse effect of Varenicline was 
nausea, which was usually not severe and reduced with time. Post 
marketing safety data suggest that Varenicline may be associated 
with depressed mood, agitation, and suicidal behaviour or idea- 
tion. Although it remains uncertain whether this represents a 
causal association, Varencline should be avoided or used with 
caution in patients with conditions or characteristics that could 
suggest an increased risk of suicide.
coMpleMentAry therApIes                                         
Hypnotherapy and acupuncture continue to be used as smoking 
cessation interventions. There are methodological difficulties in 
conducting high quality trials of these interventions. The Cochrane 
reviews failed to detect a specific effect of either hypnotherapy or 
acupuncture on smoking cessation, but practitioner attention may 
provide a non-specific effect comparable to counselling.(14,15) 
dIscussIon                                                                     
This review shows that there is evidence that a range of inter-
ventions potentially available to doctors may help their patients 
to quit smoking. What is the clinical significance of this evidence? 
Some idea of the potential impact can be gained from estimating 
the numbers needed to treat for different interventions. There are 
difficulties in estimating NNT’s from meta-analysis of trials of 
smoking cessation, principally because the absolute quit rates vary 
depending on the population under study in each trial. For brief 
advice, which is generally given to smokers who are not specifi- 
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cally selected for motivation to quit, the background quit rate is 
low. Assuming an unassisted quit rate of 2 to 3% in this popula- 
tion, brief advice can increase quitting by a further 1 to 3%, giving 
a number needed to treat of 50 - 120. Although this may seem 
like a poor success rate for the individual doctor, advice is an inex-
pensive intervention which can be offered in settings where other 
resources may be limited and cumulatively the effects would be 
large if all doctors provided it. 
Individuals taking up pharmacological treatment for smoking ces-
sation are likely to be more motivated than the general population 
of smokers, so their unassisted quit rate may be assumed to be 
higher when calculating NNT’s. Based on a median no-treatment 
(placebo) clinical trial quit rate of 7.5% the NNT for NRT is 23 
(95% CI 20 to 27), for Bupropion 18 (95% CI 14 to 23), and 
for Varenicline 10 (95% CI 7 to 14). These numbers compare 
favourably with other preventive healthcare interventions.(4)
The ability of physicians to help their patients to quit smoking will 
of course vary depending on the resources available within their 
country and locality. In South Africa, Varenicline is not yet avai- 
lable, although it is likely that it will be licensed in the near future. 
As a measure of provision of treatment for tobacco dependence, 
the World Health Organisation tracks availability of eight evidence-
based treatment resources described in this review: access to a 
national toll-free quit line, ability to purchase NRT, Bupropion and 
Varenicline, and smoking cessation support in primary care, in 
hospitals, in offices of health professionals and in the community. 
WHO’s 2009 report on the global tobacco epidemic shows wide 
variation in availability of these resources. The report found that 
seventeen mainly high-income countries provide comprehensive 
smoking cessation services encompassing in full or in part all eight 
of these resources. About a third of middle-income countries and 
less than 15% of low-income countries provide coverage for NRT 
and/or cessation services.(4) Only four middle-income countries 
and no low-income countries provide a national toll-free quit line 
and coverage for both NRT and cessation services. In the majority 
of low- and middle-income countries, the cost of cessation 
assistance is not covered by government, and 8% of middle- 
income and 29% of low-income countries provide no assistance 
to smokers. Together with measures to control supply and 
demand for tobacco, identifying the resources to increase availa-
bility of tobacco dependence treatment is a major public health 
challenge for clinicians and for the global community. 
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